ClariVest Asset Management LLC lowered its stake in shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 7.1% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 31,843 shares of the biotechnology company’s stock after selling 2,434 shares during the quarter. ClariVest Asset Management LLC’s holdings in Enanta Pharmaceuticals were worth $3,041,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in ENTA. Bank of Montreal Can grew its stake in shares of Enanta Pharmaceuticals by 33.0% in the 4th quarter. Bank of Montreal Can now owns 870 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 216 shares during the last quarter. Arizona State Retirement System grew its stake in shares of Enanta Pharmaceuticals by 6.4% in the 4th quarter. Arizona State Retirement System now owns 24,229 shares of the biotechnology company’s stock worth $1,716,000 after purchasing an additional 1,460 shares during the last quarter. Xact Kapitalforvaltning AB grew its stake in shares of Enanta Pharmaceuticals by 36.0% in the 4th quarter. Xact Kapitalforvaltning AB now owns 3,400 shares of the biotechnology company’s stock worth $241,000 after purchasing an additional 900 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Enanta Pharmaceuticals by 22.9% in the 4th quarter. Rhumbline Advisers now owns 46,753 shares of the biotechnology company’s stock worth $3,312,000 after purchasing an additional 8,722 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Enanta Pharmaceuticals in the 4th quarter worth approximately $489,000. 89.64% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts have recently issued reports on ENTA shares. BidaskClub cut shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 1st. Berenberg Bank raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $80.00 to $120.00 in a research note on Tuesday, April 23rd. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $99.00 price objective on the stock in a research note on Friday, May 10th. Finally, Wolfe Research started coverage on shares of Enanta Pharmaceuticals in a research note on Friday, May 24th. They issued an “outperform” rating and a $117.00 price objective on the stock. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $111.20.
Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Tuesday, May 7th. The biotechnology company reported $0.20 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.29. The business had revenue of $39.60 million for the quarter, compared to the consensus estimate of $40.92 million. Enanta Pharmaceuticals had a net margin of 33.28% and a return on equity of 19.25%. The firm’s quarterly revenue was down 10.0% compared to the same quarter last year. During the same period last year, the firm posted $0.61 earnings per share. As a group, research analysts predict that Enanta Pharmaceuticals Inc will post 1.9 EPS for the current year.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.
Featured Story: Analyzing a company’s cash flow statement
Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.